GlassScriptPhysician profile
Danielle Mcfarland
NPI 1285750042
$5,750.15
in general payments reported to CMS, 2019-2025
20 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $589 · 2022: $824 · 2023: $1,658 · 2024: $1,001 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,336.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,953.90 | 2021-2025 | |
| Gilead Sciences, INC. | $1,083.91 | 2021-2025 | Descovy, Livdelzi |
| Glaxosmithkline, LLC. | $256.94 | 2021-2023 | Nucala |
| Amgen INC. | $254.38 | 2023-2025 | Krystexxa, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.00 | 2024-2025 | Jardiance |
| Mylan Specialty L.P. | $247.71 | 2023-2024 | Yupelri, Yupelri |
| Janssen Pharmaceuticals, INC | $150.00 | 2025 | Invega Trinza, Invega Sustenna |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $149.99 | 2023 | Myfembree |
| Luye Pharma (USA) LTD. | $130.00 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $128.88 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.38 | 2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2025 | Entyvio |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $123.66 | 2024 | Voquezna |
| Grifols USA, LLC | $122.91 | 2025 | Xembify |
| Alkermes, INC. | $119.63 | 2025 | Vivitrol |
| Biohaven Pharmaceuticals, INC. | $105.01 | 2021 | |
| Viiv Healthcare Company | $19.85 | 2025 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mcfarland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.